This month EMA’s safety committee (PRAC) reviewed a number of safety signals related to COVID-19 vaccines. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine’s benefits and risks.
PRAC concludes review of signal of facial swelling with COVID-19 vaccine Comirnaty
PRAC has recommended a change to Comirnaty‘s product information. After reviewing all the available evidence, including cases reported to the European database for suspected side effects (EudraVigilance) and data from the scientific literature, PRAC considered that there is at least a reasonable possibility of a causal association between the vaccine and the reported cases of facial swelling in people with a history of injections with dermal fillers (soft, gel-like substances injected under the skin). Therefore, PRAC concluded that facial swelling in people with a history of injections with dermal fillers should be included as a side effect in section 4.8 of the summary of product characteristics (SmPC) and in section 4 of the patient information leaflet (PIL) for Comirnaty. The benefit-risk balance of the vaccine remains unchanged.
PRAC concludes review of unusual blood clots with low blood platelets1 with Janssen’s COVID-19 vaccine
PRAC has now concluded its review of COVID-19 Vaccine Janssen and confirmed, as previously communicated, that the benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects. In finalising the review, the Committee recommended on 20 April further refinement of the warning about thrombosis (formation of blood clots in the vessels) with thrombocytopenia (low blood platelets) syndrome, which was listed previously in the product information for COVID-19 Vaccine Janssen. The product information will now also include advice that patients who are diagnosed with thrombocytopenia within three weeks of vaccination should be actively investigated for signs of thrombosis. Similarly, patients who present with thromboembolism within three weeks of vaccination should be evaluated for thrombocytopenia. Lastly, thrombosis with thrombocytopenia syndrome will be added as an ‘important identified risk’ in the risk management plan for the vaccine. Furthermore, the marketing authorisation holder will provide a plan to further study the possible underlying mechanisms for these very rare events.
PRAC continues to closely review Comirnaty and COVID-19 Vaccine Moderna for unusual blood clots with low blood platelets2
The PRAC is closely monitoring whether mRNA vaccines might also be linked to cases of rare, unusual blood clots with low blood platelets, a side effect that has been reported in Vaxzevria and COVID-19 vaccine Janssen. Following a review of reports of suspected side effects, the PRAC considers at this stage that there is no safety signal for the mRNA vaccines. Only few cases of blood clots with low blood platelets have been reported. When seen in the context of the exposure of people to the mRNA vaccines, these numbers are extremely low, and their frequency is lower than the one occurring in people who have not been vaccinated. In addition, these cases do not seem to present the specific clinical pattern observed with Vaxzevria and COVID-19 Vaccine Janssen. Overall, the current evidence does not suggest a causal relation.
EMA will continue to monitor this issue closely and communicate further if necessary.
Topics of interests from enhanced monitoring of COVID-19 vaccines
Enhanced safety monitoring in the form of pandemic summary safety reports is one of the commitments required from the marketing authorisation holders in the context of the conditional marketing authorisation. Marketing authorisation holders are required to submit pandemic summary safety reports to EMA on a monthly basis. These reports are reviewed by the PRAC and any areaof concern further investigated, if needed.
PRAC assessing reports of Guillain-Barre syndrome with AstraZeneca’s Covid-19 vaccine
As part of the review of the regular pandemic summary safety reports for Vaxzevria, AstraZeneca’s Covid-19 vaccine, the PRAC is analysing data provided by the marketing authorisation holder on cases of Guillain-Barre syndrome (GBS) reported following vaccination. GBS is an immune system disorder that causes nerve inflammation and can result in pain, numbness, muscle weakness and difficulty walking. GBS was identified during the marketing authorisation process as a possible adverse event requiring specific safety monitoring activities. PRAC has requested the marketing authorisation holder to provide further detailed data, including an analysis of all the reported cases in the context of the next pandemic summary safety report.
PRAC will continue its review and will communicate further when new information becomes available.
PRAC assessing reports of myocarditis with Comirnaty and COVID-19 Vaccine Moderna
EMA is aware of cases of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the membrane around the heart) mainly reported following vaccination with Comirnaty. There is no indication at the moment that these cases are due to the vaccine. However, PRAC has requested the marketing authorisation holder to provide further detailed data, including an analysis of the events according to age and gender, in the context of the next pandemic summary safety report and will consider if any other regulatory action is needed. Additionally, the PRAC has requested the marketing authorisation holder for COVID-19 Vaccine Moderna – also an mRNA vaccine – to monitor similar cases with their vaccine and to also provide a detailed analysis of the events in the context of the next pandemic summary safety report. EMA will communicate further when new information becomes available.
1Thrombosis with thrombocytopenia syndrome
2Thrombosis with thrombocytopenia syndrome
Last month Moscow-based Smart Driving Labs presented its concept of connected vehicle for urban public transport. The solution reportedly “involves the installation of telematics modules with a set of sensor equipment on buses and minibuses and connection via a cellular network to a cloud platform.” The system will allow public transport companies to collect real-time data on movement, speed, sharp…
SpaceX is preparing to launch NASA’s DART (Double Asteroid Redirect Test) mission onboard a Falcon 9 rocket. DART is a demonstration mission to determine the effects of an intentional impact on an asteroid. DART’s collision with the asteroid moon Dimorphos is set for October 2022. The launch of the small spacecraft from SLC-4E at Vandenberg…
ITALY NEWS: Photo Credit: Times Now New Delhi – Vincenzo De…
ITALY NEWS: Italian gas group Snam logo is seen outside…
What is Nevada? That’s the question that came to my mind after reading Kevin D. Williamson’s What is Texas? a few weeks ago, which analyzed the mythology Texans create for themselves, the mythology we create for Texans, and how the two intertwine and define Texan life. Texas, you must understand, is big — with apologies…
Most Popular Articles on dWeb.News
- BUSINESS: NWEA, Center For Education Policy Research At Harvard University, And CALDER At The American Institutes For Research Announce New Initiative To Help Examine District COVID-19 Recovery Efforts
- FRONT PAGE: Magnus Medical Launches With Breakthrough Device Designation For Rapid, Individualized Treatment Of Major Depression And $25M In Series A Financing
- Brooklyn Business Owner Charged with Bank Fraud, Identity Theft and Witness Tampering
- SCIENCE NEWS: Researchers discover new insights about tau proteins in people living with ALS
- AFRICA NEWS: Zimbabwe: President to Commission Amarula Processing Plant
- BUSINESS: New Book by Louis Gallo – Why Is There Something Rather Than Nothing: Poems
- Front Page: Macron And Modi Vow To 'act Jointly' After Subs Dispute
- Food Safety: Cubano sandwiches with Clostridium perfringens discovered in Alaska examination
- TECH NEWS: Kill Wi-Fi dead spots with this TP-Link mesh router 3-pack for $110
- Pokemon Unite All Rounder Guide: Moves Lists, Stats And Strategies For All All-Rounder Type Pokemon